公开(公告)号：WO2021207599A1

公开(公告)日：2021-10-14

申请号：PCT/US2021/026577

申请日：2021-04-09

申请人： AKSTON BIOSCIENCES CORPORATION

发明人： ZION, Todd C. ,  LANCASTER, Thomas M. ,  SATHIYASEELAN, Thillainayagam ,  HUANG, Kexin

IPC分类号： C07K14/005 ,  A61K39/12 ,  A61P31/14 ,  A61K38/00 ,  A61K2039/54 ,  A61K2039/55566 ,  A61K2039/55588 ,  A61K2039/6031 ,  A61K2039/6056 ,  A61K2039/6075 ,  A61K2039/62 ,  A61K39/215 ,  C07K14/165 ,  C07K2319/30 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N7/00

摘要： The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (CQVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naive patients to produce antibodies to the S ARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

公开(公告)号：WO2018107117A1

公开(公告)日：2018-06-14

申请号：PCT/US2017/065456

申请日：2017-12-08

申请人： AKSTON BIOSCIENCES CORPORATION

发明人： LANCASTER, Thomas M. ,  ZION, Todd C. ,  SATHIYASEELAN, Thillainayagam ,  MURIKIPUDI, Sylaja

IPC分类号： A61K38/00 ,  A61K38/28 ,  C07K14/435 ,  C07K14/62 ,  C07K19/00

摘要： The present disclosure relates generally to compositions of insulin-Fc ( e.g. , proinsulin-Fc) fusion proteins and their use to treat autoimmune disease, e.g. , autoimmune diabetes, e.g. , Type 1 diabetes.